ALLO-647 + Fludarabine + Cyclophosphamide

Phase 1Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Conditions

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Trial Timeline

Feb 24, 2021 → Dec 1, 2025

NCT ID

NCT04696731

About ALLO-647 + Fludarabine + Cyclophosphamide

ALLO-647 + Fludarabine + Cyclophosphamide is a phase 1 stage product being developed by Allogene Therapeutics for Advanced/Metastatic Clear Cell Renal Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04696731. Target conditions include Advanced/Metastatic Clear Cell Renal Cell Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05714345	Phase 2	Terminated	Nov 1, 2023	Oct 28, 2024	Relapsed/Refractory Large B Cell Lymphoma
NCT05000450	Phase 1/2	Terminated	Jun 6, 2021	Oct 11, 2023	Relapsed/Refractory Multiple Myeloma
NCT04696731	Phase 1	Active	Feb 24, 2021	Dec 1, 2025	Advanced/Metastatic Clear Cell Renal Cell Carcinoma
NCT04416984	Phase 1/2	Active	May 21, 2020	May 1, 2029	Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
NCT03939026	Phase 1	Completed	May 1, 2019	Jan 28, 2025	Relapsed/Refractory Large B Cell Lymphoma

Competing Products

20 competing products in Advanced/Metastatic Clear Cell Renal Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib	Sun Pharmaceutical	Phase 1	33
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU	Eisai	Phase 3	77
PF-05082566 + KW-0761	Kyowa Kirin	Phase 1	33
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)	Merck	Phase 3	77
MK-4464 + Pembrolizumab + 89Zr-MK-4464	Merck	Phase 1	33
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)	Merck	Phase 1/2	41
Selumetinib + Pembrolizumab	Merck	Phase 1	33
BJ-001 + Pembrolizumab	Merck	Phase 1	33
ADG116	Merck	Phase 1	33
Gebasaxturev IV + Gebasaxturev ITu + Pembrolizumab	Merck	Phase 2	52
ADU-S100 + ipilimumab	Novartis	Phase 1	33
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine	Roche	Phase 2	52
Selicrelumab + Vanucizumab + Bevacizumab	Roche	Phase 1	33
AMG 510	Amgen	Phase 1	32
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1	Pfizer	Phase 1/2	40
PF-08046876	Pfizer	Phase 1	32
Capecitabine + Sunitinib	Pfizer	Phase 2	51
IBI308	Innovent Biologics	Phase 1	32
MM-121 + Paclitaxel	Sanofi	Phase 1	32
Ubamatamab + REGN7075 + Sarilumab	Regeneron Pharmaceuticals	Phase 2	51

Other Products from Allogene Therapeutics

Fludarabine + CyclophosphamidePhase 2

ALLO-647 + Fludarabine + CyclophosphamidePhase 2

ALLO-647 + Fludarabine + CyclophosphamidePhase 1/2

CyclophophamidePhase 1